London-based Isomorphic Labs confirmed a $5 billion infusion in a Series C financing that will speed the rollout of its proprietary drug-design platform. The capital arrives six months after a $2.1 billion raise and reflects strong confidence from a blend of venture firms and Alphabet’s own investment arms.
Funding round and investor lineup
The financing was co-led by Greenoaks and Sequoia Capital, with additional commitment from Andreessen Horowitz (a16z) and several fresh backers. Existing supporters such as Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund participated alongside continued, sizable contributions from Alphabet. The round was described as oversubscribed, indicating demand that exceeded the amount on offer.
Lead investors
Greenoaks highlighted the company’s ability to scale deep-learning models that improve with more data and compute, while Sequoia emphasized the discovery of scaling laws in Isomorphic’s technology. Both firms cited the platform’s potential to transform the economics of drug development.
Existing backers
Long-standing investors reaffirmed their confidence, signalling that the strategic partnership between Isomorphic and Alphabet remains a cornerstone of the company’s growth plan. The collective backing brings together venture capital expertise, sovereign wealth resources and corporate tech acumen.
AI platform and therapeutic pipeline
At the heart of the operation lies IsoDDE, an AI-driven drug design engine that unifies a suite of foundational simulation models. These models operate across multiple therapeutic areas and drug modalities, exploring vast chemical spaces to generate molecules with optimized drug-like properties. The system’s predictions approach experimental accuracy, allowing researchers to iterate designs rapidly.
Preclinical progress
Isomorphic reports encouraging preclinical data from internal oncology and immunology programs, as well as from collaborations with partners such as Eli Lilly, Novartis and Johnson & Johnson. More than twenty candidate programs are active, and the company aims to move a substantial portion toward first-in-human trials by the end of 2026.
Future roadmap and market impact
The fresh capital will be allocated to three priority areas: deepening the foundations of the simulation models, expanding the platform to cover additional modalities, including large-molecule biologics, and building a global, AI-first infrastructure for translational and clinical development. Executives stress that the ultimate goal is a platform capable of producing “hundreds of drugs a year,” a scale that could reshape R&D economics.
Clinical ambitions
Chief Executive Sir Demis Hassabis reiterated the ambition to file regulatory submissions on schedule and to showcase AI-designed molecules in human trials. While no regulator has yet approved a drug designed entirely by AI, the company expects its first trial data to emerge in 2027.
Strategic partnerships
Beyond capital, the round deepens relationships with pharma giants and technology partners. By providing them access to IsoDDE’s simulation suite, Isomorphic hopes to accelerate joint discovery projects, thereby broadening the ecosystem of AI-enhanced therapeutics.



